Lipopolysaccharide (LPS) induced Depression Model Development Service

Are you currently facing challenges in developing novel therapies for neuropsychiatric disorders, particularly those linked to inflammation? Our Lipopolysaccharide (LPS)-induced depression model development service helps you accelerate drug discovery by providing a robust and clinically relevant preclinical platform. We enable you to evaluate immunomodulatory drug candidates with precision through a highly reproducible in vivo model of neuroinflammation. Our expertise ensures you get the data you need to drive your project forward.

The LPS-induced depression model is a leading in vivo platform for neuroinflammation research. It reliably generates a depressive-like phenotype by introducing a peripheral inflammatory stimulus. This model is particularly powerful because it replicates a key pathological mechanism observed in a significant subpopulation of human depression patients. Our approach leverages this model to provide comprehensive insights, ensuring the data generated is relevant and translatable to clinical studies.

How Our LPS-Induced Depression Model Development Service Can Assist Your Project

This service provides a clear, actionable path to obtaining high-quality preclinical data for your compounds. We provide a partnership from concept to conclusion, ensuring the entire process is streamlined and efficient.

Discover How We Can Help - Request a Consultation

Workflow

Our comprehensive workflow is designed to provide you with a detailed, step-by-step process that can be tailored to your specific research needs.

Why Choose Us?

Creative Biolabs is a leader in preclinical modeling, offering unparalleled expertise and a commitment to your project's success. Our service is distinguished by its scientific rigor, comprehensive approach, and collaborative partnership model.

Experience the Advantage - Get a Quote Today

Customer Reviews

• "Using CBL's LPS-induced depression model development service in our research has significantly improved our ability to screen anti-inflammatory compounds. The data on microglia activation was particularly useful and helped us confidently select our lead candidate for further development." - Js D*e, R&D Director
• "The expertise and flexibility of the CBL team were invaluable. They helped us understand the specific inflammatory pathways affected by our compound, providing a level of mechanistic insight far beyond what we could have achieved on our own." - Ma R*z, Senior Scientist
• "The quality of the biomarker analysis was outstanding. We were able to confirm that our compound not only had a behavioral effect but also a quantifiable impact on key inflammatory cytokines, providing strong evidence for our a novel mechanism of action." - Ec P*n, Research Fellow

Lipopolysaccharide (LPS)-Induced Depression Model

The LPS-induced depression model is a leading in vivo platform for neuroinflammation research. It reliably generates a depressive-like phenotype by introducing a peripheral inflammatory stimulus. This model is particularly powerful because it replicates a key pathological mechanism observed in a significant subpopulation of human depression patients. Our approach leverages this model to provide comprehensive insights, ensuring the data generated is relevant and translatable to clinical studies.

Fig.1 Experimental design. Behavioral changes of mice after MS/LPS and fluoxetine administration.¹

What We Can Offer

At CBL, our LPS-induced depression model development service is not just a standard protocol; it is a customizable and comprehensive solution designed to meet your unique research needs. We understand that one size does not fit all, and our expertise allows us to provide a high-end service that is both reliable and flexible.

• Customized Study Design: We can optimize the model by adjusting parameters such as animal strain, LPS dosage, and the route and timing of administration to perfectly align with your compound's properties and research goals.
• Comprehensive Upstream and Downstream Analysis: Our services include robust upstream and downstream process development. We not only induce the model effectively but also provide a full suite of analytical tools to quantify your results, including advanced cytokine profiling and neurochemical analysis.
• Seamless Integration: We can integrate our LPS model with your existing research pipeline, ensuring a smooth transition from preclinical screening to further stages of drug development.
• High-Standard Quality Control: Our well-established quality system and rigorous aseptic verification procedures ensure the highest quality of data. We utilize sophisticated quality control tools to provide you with reliable and reproducible results, every time.
• Expert Consultation: Our team of seasoned neurobiologists is available to provide expert guidance and support throughout the entire project, ensuring your success.

Related Services

We offer a full suite of complementary preclinical services to support your drug development program. These services can be combined with our LPS model to provide a more holistic understanding of your compound's effects.

• Target Identification & Validation
• Compound Screening & Profiling
• Pharmacokinetic/Pharmacodynamic (PK/PD) Studies
• Neuroinflammation Research Models

FAQs

Ready to accelerate your research? Our team of experienced neurobiologists is here to answer your questions and help you design the perfect study.

Contact Our Team for More Information and to Discuss Your Project.

Reference

1. Yu, Xiaojin, et al. "Comparison of LPS and MS-induced depressive mouse model: behavior, inflammation and biochemical changes." BMC psychiatry 22.1 (2022): 590. Distributed under Open Access license CC BY 4.0, without modification. https://bmcpsychiatry.biomedcentral.com/articles/10.1186/s12888-022-04233-2#Sec18